Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Company Overview - Praxis Precision Medicines, Inc. (PRAX) is expected to report a quarterly loss of $2.91 per share, reflecting a year-over-year change of +2$0.48 million, which is a decrease of 7.7% from the same quarter last year [3] Earnings Estimates and Trends - The consensus EPS estimate has been revised 0.49% lower in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Praxis is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.07% [10][11] - The company currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11] Earnings Surprise History - In the last reported quarter, Praxis was expected to post a loss of $2.01 per share but actually reported a loss of$2.75, resulting in a surprise of -36.82% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Context - Intellia Therapeutics, Inc. (NTLA), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.32 per share, with revenues projected at$8.82 million, reflecting a significant year-over-year increase of 559.4% [17] - Intellia's consensus EPS estimate has been revised 2.5% higher in the last 30 days, and it has an Earnings ESP of 35.03%, indicating a strong likelihood of beating the consensus EPS estimate [18]